A recent meta-analysis, assessing the impact of BCR or BCL-2 inhibitor treatments on progression free survival (PFS) of refractory and relapsed (R/R) CLL patients, reported that BCR/BCL-2 inhibition increased PFS of del(11q) patients significantly compared to non-del(11q) patients [40]. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.